Tema GLP-1, Obesity & Cardiometabolic ETF (HRTS) News

Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary

Kura Oncology, Inc. (NASDAQ:KURA) on Wednesday announced $50 million financing tied to advancing its menin-inhibition strategy.Launches Caspian Therapeutics With $50 Million FinancingKura said it is

Benzinga21:57

Reported September 8, 2026: 'Tylenol Use In Pregnancy May Be Linked With Uterus, Ovary Changes In Daughters' - Reuters News

Reported September 8, 2026: 'Tylenol Use In Pregnancy May Be Linked With Uterus, Ovary Changes In Daughters' - Reuters

Benzinga21:51

Pyxis Slides After New Early-stage Trial Data for Lead Asset in Head and Neck Cancer

Seeking Alpha20:43

Medicare's $2,000 Drug Cap Is Getting Expensive — More Than 1 in 5 Seniors Hit It as Drug Spending Heads Toward $346 Billion

Health policy analysts are raising concerns about the rising cost of Medicare's prescription drug program after more than 1 in 5 Medicare Part D enrollees hit the program's $2,000 out-of-pocket drug

Benzinga20:39

Actuate Therapeutics Says Preclinical Studies Showed Synergistic Activity Of Elraglusib Combined With Revolution Medicines' Zoldonrasib And Daraxonrasib In Pancreatic Cancer Models

Actuate Therapeutics Says Preclinical Studies Showed Synergistic Activity Of Elraglusib Combined With Revolution Medicines' Zoldonrasib And Daraxonrasib In Pancreatic Cancer

Benzinga19:10

Kura Oncology Announces Launch Of Caspian Therapeutics With $50M Financing Led By BVF Partners, With Eli Lilly Participating, To Advance Menin Inhibitor KO-7246 In Diabetes; Retains About Half Ownership

Kura Oncology Announces Launch Of Caspian Therapeutics With $50M Financing Led By BVF Partners, With Eli Lilly Participating, To Advance Menin Inhibitor KO-7246 In Diabetes; Retains About Half

Benzinga19:07

'FDA's Acting Drug, Vaccine Regulators Tapped for Permanent Roles'- Bloomberg

'FDA's Acting Drug, Vaccine Regulators Tapped for Permanent Roles'-

Benzinga04:20

If You Invested $1000 In Thermo Fisher Scientific Stock 15 Years Ago, You Would Have This Much Today

Thermo Fisher Scientific (NYSE:TMO) has outperformed the market over the past 15 years by 4.35% on an annualized basis producing an average annual return of 17.57%. Currently, Thermo Fisher

Benzinga00:00

Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates

Inhibrx Biosciences Inc. (NASDAQ:INBX) announced primary endpoint results from the randomized Phase 2 portion of its HexAgon study.• Inhibrx Biosciences stock is taking a hit today. What's behind

BenzingaSep 8 23:29

Baron Durable Advantage Fund Initiates Arxis, Exits Intuit and Thermo Fisher Among Q2 Moves

Seeking AlphaSep 8 22:20

Why Is Eli Lilly Stock Falling Tuesday?

Eli Lilly & Co. (NYSE:LLY) stock is down about 2% on Tuesday as a broader risk-off move pressures large-cap healthcare stocks. The Nasdaq is down 0.29%, while the S&P 500 has fallen 0.43%.

BenzingaSep 8 22:19

Johnson & Johnson To Present Data Across Its Neuropsychiatry Portfolio at 2026 Psych Congress Annual Meeting

Johnson & Johnson (NYSE:JNJ) today announced that 24 abstracts featuring clinical data and real-world evidence across the neuropsychiatry portfolio will be presented at the 2026 Psych Congress

BenzingaSep 8 20:03

8 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity

BenzingaSep 8 01:35

$100 Invested In UnitedHealth Group 20 Years Ago Would Be Worth This Much Today

UnitedHealth Group (NYSE:UNH) has outperformed the market over the past 20 years by 1.51% on an annualized basis producing an average annual return of 10.72%. Currently, UnitedHealth Group has a

BenzingaSep 8 00:45

Day 3 of the 2026 National Reimbursement Drug List (NRDL) negotiations: Intensive talks on new "-tinib" drugs as star companies such as BeiGene and Kelun Biotech take the stage.

1) Intensive negotiations for new "-tinib" class drugs took place in the morning, with innovative pharmaceutical companies such as InnoCare Pharma, Shouyao Holdings, and Jiangsu Wellshine making successive appearances; 2) In the afternoon session, leading pharmaceutical firms including Kelun Biotech and BeiGene were featured, engaging in a two-pronged strategic dynamic in the ADC sector characterized by "expansion within the catalog" and "new additions outside the catalog."

cls.cnSep 7 16:20

Day 2 of the 2026 National Reimbursement Drug List (NRDL) negotiations: Two CAR-T therapies vie for basic medical insurance coverage as executives from multiple companies maintain on-site presence.

1. As the national reimbursement drug negotiations entered their second day, several innovative drugs and products with high clinical value were brought to the negotiating table; 2. In line with past practice, innovative drugs that are relatively more difficult to negotiate, such as anti-cancer medications and treatments for rare diseases, tend to be scheduled more intensively in the subsequent days. The lineup of participating companies suggests that this arrangement has largely been maintained.

cls.cnSep 7 07:53

Notable Healthcare Headlines for the Week: UnitedHealth, Moderna, and Medtronic in Focus

Seeking AlphaSep 6 21:05

On-the-ground report from Day 2 of the 2026 NRDL negotiations: Blockbuster oncology drugs, including CAR-T therapies and the world’s first bispecific antibody-drug conjugate (ADC), made their debut, while products covered by commercial insurance sought to

① On the second day of national reimbursement negotiations, the focus shifted to innovative oncology drugs, with nearly 20 companies—including Hengrui Medicine, Eli Lilly and Co, Novartis, and Innovent Biologics—participating in the morning session; ② In the afternoon, multinational pharmaceutical firms took center stage, with Merck & Co, Roche, and Johnson & Johnson successively entering negotiations as several blockbuster innovative drugs were brought to the table; ③ Companies such as Heyuan Biopharma and JW Therapeutics, which emerged as new entrants in commercial health insurance formularies last year, are once again attempting to break into the basic medical insurance scheme, marking the transition of dual-formulary alignment into the practical implementation phase.

cls.cnSep 6 15:29

Key Deals This Week: Flex, Nvidia, AbbVie and More

Seeking AlphaSep 6 03:15

Healthcare August Recap: Moderna Jumps 156% as Biotech Shines; DaVita Sinks

Seeking AlphaSep 5 23:05